Program
dulaglutide
Also written as “Dulaglutide”, “LY2189265” and “Dulaglutide (Reference)”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Cardiovascular Diseases, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 451 open or running | phase 4since Apr 21, 2016 | Feb 28, 2008 | Dec 2027phase 3 · NCT06739122 |
| CSPC Pharmaceutical Group | 10 open or running | phase 3since Jan 23, 2024 | Jan 23, 2024 | none ahead |
| Innovent Biologics | 10 open or running | phase 3since Oct 19, 2022 | Oct 19, 2022 | none ahead |
Also a collaborator on its studies: united-biosource-llc and tessella-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 32 studies since Feb 28, 2008.
- Nov 10, 2016Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT02963766 · 154 enrolled · United States, Brazil, France and more
- Nov 22, 2016Phase 2 study in Diabetes Mellitus, Type 2Eli Lilly · NCT02973100 · 318 enrolled · United States, Czechia, Mexico and more
- Oct 17, 2017Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT03315780 · 12 enrolled · Japan
- Dec 1, 2017Phase 1 study in HealthyEli Lilly · NCT03363906 · 27 enrolled · United States
- Apr 2, 2018Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT03495102 · 1,842 enrolled · United States, Argentina, Austria and more
- Oct 16, 2020Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT04591626 · 291 enrolled · China
- Nov 20, 2020Phase 1 study in Diabetes Mellitus, Type 2Eli Lilly · NCT04641312 · 67 enrolled · Germany
- Mar 19, 2021Phase 3 study in Diabetes MellitusEli Lilly · NCT04809220 · 591 enrolled · Japan
- May 16, 20222 phase 1 studies in Diabetes Mellitus, Type 2Eli Lilly · NCT05377333, NCT05407961
- Oct 19, 2022Innovent Biologics's first study: phase 3 study in Diabetes Mellitus, Type 2New to Innovent BiologicsInnovent Biologics · NCT05606913 · 731 enrolled · China
- Dec 15, 2022Phase 4 study in Diabetes Mellitus, Type 2Eli Lilly · NCT05659537 · 212 enrolled · India
- Jan 23, 2024CSPC Pharmaceutical Group's first study: phase 3 study in Diabetes Mellitus, Type 2New to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06235086 · 632 enrolled · China
- Dec 13, 2024Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT06739122 · 55 planned · United States, Argentina, Mexico
- Dec 18, 2025Phase 1 study in Diabetes Mellitus, Type 2Eli Lilly · NCT07313813 · 20 enrolled · Singapore
Ahead
- Dec 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT06739122
TargetBeta
“A glucagon-like peptide-1 (GLP-1) receptor agonist that is 90% homologous to native human GLP-1 (7-37) and is composed of a dipeptidyl peptidase-IV-protected GLP-1 analog covalently ”NCIt, by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Liraglutiderule | Novo Nordisk | phase 4 | 116 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
| efpeglenatiderule | Hanmi Pharmaceutical | phase 3 | 13 |
Studies
All 47 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07313813Diabetes Mellitus, Type 2 · Singapore | 1 | Completed | Eli Lilly | Aug 13, 2026 | 20 |
| NCT06739122Diabetes Mellitus, Type 2 · United States, Argentina, Mexico | 3 | Recruiting | Eli Lilly | Dec 2027 | 55 |
| NCT06235086Diabetes Mellitus, Type 2 · China | 3 | Completed | CSPC Pharmaceutical Group | Feb 3, 2026 | 632 |
| NCT05659537Diabetes Mellitus, Type 2 · India | 4 | Completed | Eli Lilly | Jan 16, 2024 | 212 |
| NCT05606913Diabetes Mellitus, Type 2 · China | 3 | Completed | Innovent Biologics | Jan 26, 2024 | 731 |
| NCT05407961Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Eli Lilly | Jan 12, 2024 | 90 |
| NCT05377333Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eli Lilly | Nov 22, 2023 | 94 |
| NCT04809220Diabetes Mellitus · Japan | 3 | Completed | Eli Lilly | Oct 1, 2022 | 591 |
| NCT04641312Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Eli Lilly | Dec 21, 2021 | 67 |
| NCT04591626Diabetes Mellitus, Type 2 · China | 3 | Completed | Eli Lilly | Apr 28, 2022 | 291 |
| NCT03495102Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more | 3 | Completed | Eli Lilly | May 28, 2019 | 1,842 |
| NCT03363906Healthy · United States | 1 | Completed | Eli Lilly | Jun 6, 2018 | 27 |
| NCT03315780Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Eli Lilly | Feb 28, 2018 | 12 |
| NCT02973100Diabetes Mellitus, Type 2 · United States, Czechia, Mexico and more | 2 | Completed | Eli Lilly | Jul 15, 2017 | 318 |
| NCT02963766Diabetes Mellitus, Type 2 · United States, Brazil, France and more | 3 | Completed | Eli Lilly | Jun 12, 2021 | 154 |
| NCT02750410Diabetes Mellitus, Type 2 · Japan | 4 | Completed | Eli Lilly | Jun 18, 2018 | 159 |
| NCT02597049Diabetes Mellitus, Type 2 · United States, Austria, Czechia and more | 3 | Completed | Eli Lilly | Feb 2017 | 424 |
| NCT02152371Diabetes Mellitus, Type 2 · United States, Czechia, Hungary and more | 3 | Completed | Eli Lilly | Oct 2015 | 300 |
| NCT01769378Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more | 3 | Completed | Eli Lilly | Dec 2014 | 300 |
| NCT01667900Diabetes Mellitus, Type 2 · China | 1 | Completed | Eli Lilly | Jun 2014 | 58 |
| NCT01644500Diabetes Mellitus, Type 2 · China, Korea, Republic of, Taiwan | 3 | Completed | Eli Lilly | Aug 2014 | 737 |
| NCT01648582Diabetes Mellitus, Type 2 · China, Korea, Republic of, Mexico and more | 3 | Completed | Eli Lilly | Aug 2014 | 774 |
| NCT01624259Diabetes Mellitus, Type 2 · United States, Czech Republic, Germany and more | 3 | Completed | Eli Lilly | Nov 2013 | 599 |
| NCT01621178Diabetes Mellitus, Type 2 · United States, Brazil, Hungary and more | 3 | Completed | Eli Lilly | Jun 2016 | 577 |
| NCT01584232Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Eli Lilly | Jul 2013 | 361 |
| NCT01558271Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Eli Lilly | Oct 2013 | 492 |
| NCT01524770Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eli Lilly | Jun 2012 | 50 |
| NCT01458210Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eli Lilly | Feb 2012 | 22 |
| NCT01436201Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eli Lilly | Nov 2011 | 24 |
| NCT01432938Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eli Lilly | Dec 2011 | 28 |
| NCT01408888Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eli Lilly | Apr 2012 | 29 |
| NCT01394952Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Aug 21, 2018 | 9,901 |
| NCT01324388Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eli Lilly | Aug 2011 | 51 |
| NCT01301092Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eli Lilly | Aug 2011 | 30 |
| NCT01300260Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Eli Lilly | Aug 2011 | 32 |
| NCT01253304Diabetes Mellitus, Type 2 · Germany, Hungary | 1 | Completed | Eli Lilly | Nov 2011 | 26 |
| NCT01250834Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Mar 2011 | 27 |
| NCT01215968Diabetes Mellitus, Type 2 · United Kingdom | 1 | Completed | Eli Lilly | Jul 2011 | 38 |
| NCT01191268Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | Feb 2012 | 884 |
| NCT01149421Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 2 | Completed | Eli Lilly | Sep 2011 | 755 |
| NCT01126580Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Completed | Eli Lilly | Nov 2011 | 807 |
| NCT01075282Diabetes Mellitus, Type 2 · Argentina, Australia, Belgium and more | 3 | Completed | Eli Lilly | May 2012 | 810 |
| NCT01064687Diabetes Mellitus, Type 2 · United States, Argentina, Mexico and more | 3 | Completed | Eli Lilly | Nov 2011 | 978 |
| NCT01001104Diabetes Mellitus, Type 2 · Japan | 2 | Completed | Eli Lilly | Dec 2010 | 145 |
| NCT00791479Diabetes Mellitus, Type 2 · United States, Croatia, Denmark and more | 2 | Completed | Eli Lilly | Jan 2010 | 167 |
| NCT00734474Diabetes Mellitus, Type 2 · United States, Canada, France and more | 3 | Completed | Eli Lilly | Jun 2011 | 1,202 |
| NCT00630825Diabetes Mellitus, Type 2 · United States, Puerto Rico | 2 | Completed | Eli Lilly | Jan 2009 | 262 |
How it is read
Names in the registry
- “Dulaglutide”, 25 entries
- “LY2189265”, 18 entries
- “dulaglutide”, 2 entries
- “Dulaglutide (Reference)”, 1 entry
- “Dulaglutide (Test)”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 44 studies
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.